News

Ligand Pharmaceuticals Spins Off Pelican Technology Holdings and Merges with Primordial Genetics

1 Mins read

Ligand Pharmaceuticals recently announced its decision to spin off its subsidiary, Pelican Technology Holdings, and merge it with Primordial Genetics. The newly formed private company, called Primrose Bio, will primarily focus on the field of synthetic biology.

As part of the deal, Ligand will maintain ownership of the existing commercial royalties associated with the Pelican Expression Technology and hold a 49.9% stake in the merged entity.

In addition to this, Ligand will be contributing $15 million to Primrose Bio in exchange for a portion of the economic rights to certain products. While this divestiture will result in lower contract revenue for Ligand in the current year, it is expected to have a positive impact on the company’s adjusted earnings.

Ligand’s full-year revenue forecast now stands at $124 million to $126 million, as compared to the previous guidance of $124 million to $128 million. The company also anticipates adjusted earnings per share for the full year to be in the range of $5.10 to $5.25, surpassing the previous forecast of $4.85 to $5.

Related posts
News

School curriculum resources to teach children about risks of in-game purchases

3 Mins read
The Oak National Academy – an arm’s length body to help schools deliver curriculum content – has launched a package of teaching…
News

Endeavour Silver is Producing First Batch of Concentrate at the Terronera Mine; Remains on Track for Wet Commissioning in Early Q2

3 Mins read
VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) — Endeavour Silver Corp. (“Endeavour” or the “Company”) (NYSE: EXK; TSX: EDR) provides a…
News

Columbia, South carolina - América Digital

4 Mins read
Partners they which have a playing table designated along with it is possible to wagers to really make the video game accessible…

Leave a Reply

Your email address will not be published. Required fields are marked *